Focused On-demand Library for Serine/threonine-protein kinase ATR

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q13535

UPID:

ATR_HUMAN

Alternative names:

Ataxia telangiectasia and Rad3-related protein; FRAP-related protein 1

Alternative UPACC:

Q13535; Q59HB2; Q7KYL3; Q93051; Q9BXK4

Background:

Serine/threonine-protein kinase ATR, also known as Ataxia telangiectasia and Rad3-related protein, plays a pivotal role in the DNA damage response. It activates checkpoint signaling upon genotoxic stresses such as ionizing radiation, ultraviolet light, or DNA replication stalling. ATR phosphorylates key proteins involved in DNA repair, recombination, and apoptosis, including BRCA1 and p53, and is essential for maintaining genomic stability.

Therapeutic significance:

ATR's involvement in Seckel syndrome 1 and Cutaneous telangiectasia and cancer syndrome, familial, underscores its potential as a therapeutic target. Understanding the role of Serine/threonine-protein kinase ATR could open doors to potential therapeutic strategies for these and other DNA damage-related disorders.